Entering August, the Hang Seng Index has seen a less-than-smooth trajectory, forming a double top in the early part of the month before sliding steadily, with the latest pullback reaching the 30-day moving average. Renewed tensions in the Middle East have put the market in a difficult position, with the blockade of the strait continuing to exert pressure on the global economy. The Federal Reserve is set to release the minutes of its July 28-29 meeting on August 19 at 2:00 PM ET. The latest non-farm payroll data surprised to the downside, and if hawkish rhetoric persists, it could negatively impact the market.
Currently, earnings reports are the primary factor influencing market sentiment. A point of caution is the slowdown in earnings for consumer leaders like Kweichow Moutai (600519.SH) and JD.com (09618). As a result, the real estate sector has become one of the few areas where policy initiatives can be observed. In the technology sector, following indiscriminate selling last month, some stocks are beginning to see a recovery rally from the bottom.
On August 14, Guangdong Province launched its first specialized financial product for the token economy, the "Token Loan," in the Haizhu District of Guangzhou, concurrently unveiling the supporting "Token Eight Measures" policy. The true innovation of the "Token Loan" lies in transforming a token from a technical unit of measurement into an asset that can be recognized by banks and used as collateral for financing. DeepSeek officially announced its new pricing for the full V4 series, confirming a price floor for tokens. Token concept stocks have been strengthened, and computing power stocks have also strengthened again, supported by policy backing.
There are many catalysts for robotics. Yushu Technology is expected to go public around August 18-24. The 2026 World Robot Conference will be held from August 19 to 23 at the Beijing Economic-Technological Development Area, with the theme "Human-Robot Symbiosis, Coexistence of Production and Demand." The focus will be on stocks with solid earnings. Tensions have re-emerged between China and Japan. On August 16, Japan's revised Foreign Exchange and Foreign Trade Act took effect, implementing a three-tier control system: ultra-high-precision five-axis CNC machine tools, core components like grating rulers, precision rotary tables, and electric spindles, and commissioning, upgrade, and original factory maintenance technology. Exports have been changed from "bulk licensing" to "case-by-case review," extending the approval cycle from about 15 days to 45-180 days, with a rejection rate exceeding 80% in sensitive areas. Old orders have been granted a grace period only until the end of 2026. This supply cutoff is accelerating the push for domestic substitution. Meanwhile, countermeasures are expected to follow.
The Hang Seng Indexes Company will announce the results of its quarterly review for the second quarter of 2026 on Friday, August 21, 2026. Stocks that may be included could see speculative activity.
Over the past month, INSILICO (03696) has nominated two potential first-in-class (FIC) preclinical candidate (PCC) pipelines. Both pipelines benefit from AI-driven discovery of novel mechanisms. Following the TNIK target, these new pipelines around two new target mechanisms and disease areas continue to validate the company's end-to-end AI platform's reproducibility, accuracy, and scalability. The capability for AI-driven discovery of novel mechanisms is also being continuously strengthened. Both pipelines focus on larger disease markets, potentially unlocking future growth for the company. Target Z/ISM9528 targets the trillion-dollar pain market. Target Z is a non-opioid, non-ion channel innovative mechanism of action discovered with the help of PandaOmics. Drug candidates for Target Z show therapeutic potential comparable to or even exceeding existing treatments, including morphine. Target Y/ISM9077: Target Y plays a key role in the biological mechanisms of aging and various age-related diseases. Inhibitors developed against Target Y, based on the AI platform, have the potential for multi-effect use in a single drug. The nominated ISM9077 is for treating dry age-related macular degeneration (Dry AMD) and other ophthalmic diseases. Its innovative mechanism of action also supports expansion into broader therapeutic areas, including Parkinson's disease, MASH, obesity, and other inflammation-related diseases. In some key evaluation indicators, it has shown approximately three times the efficacy of currently available treatments, along with improved histopathological improvement effects. The company's progress in out-licensing deals has exceeded expectations, with nine major collaborations signed in 2026 valued at over $250 million, providing strong certainty for the company's full-year earnings growth. The company is expected to continue expanding partnerships in the second half of 2026 and advance multiple PCC nomination projects, further enhancing short-term revenue growth certainty and long-term pipeline value creation.
Yushu Technology is set to debut on the A-share market, becoming the first pure-play humanoid robot stock. The company's core advantages lie in fully in-house developed hardware and strong motion control capabilities: core components like joint modules, encoders, and actuators are highly self-manufactured. It uses a route of high-torque motors paired with low-reduction-ratio planetary gear reducers, replacing traditional harmonic drive solutions. This reduces the cost of core components by 60%-70% compared to external procurement, supporting the robots in performing high-difficulty maneuvers and significantly shortening product delivery times. In 2025, the company sold over 5,000 humanoid robots with a gross margin of 63%, and over 20,000 quadruped robots with a gross margin of 57%, with profitability levels significantly higher than the manufacturing average. At the industry level, the hardware for humanoid robots has largely met the conditions for large-scale deployment. The core bottleneck for industrialization is the large language model (LLM). The industry is currently in a "from 1 to 10" development stage. Motion control capabilities alone cannot support long-term commercialization; LLMs are needed to give robots generalizable interaction capabilities, allowing them to autonomously complete complex, long-horizon tasks without being tied to fixed programs. Nearly half of the funds raised from Yushu's IPO are allocated to model research and development, confirming this core direction for the industry. In terms of technological evolution, humanoid robot LLMs are advancing along three main lines: richer modalities, increased action output frequency, and enhanced generalization capabilities. The technical route is gradually shifting from the Transformer architecture towards generative and fast-slow brain dual-system iterations. Google's latest Gemini Robotics Two has achieved breakthroughs in whole-body joint coordinated control and simulation data training, but insufficient fine force control and the lack of tactile modality remain common industry shortcomings. The industry is currently caught in a cycle of "insufficient intelligence - no real-world application scenarios - lack of real data - slow iteration." Various regions are working to break this cycle by building data collection centers to accumulate high-quality data. The future direction of the industry will involve upgrading towards tactile multi-modal fusion, world model development, and the integration of virtual and real data. In the Hong Kong stock market, focus on the whole-machine player UBTECH (09880); core components and sensing layer companies including Hesai (02525), RoboSense (02498), Sanhua Intelligent Controls (02050), JL Mag Rare-Earth (06680), and Johnson Electric Holdings (00179); and industrial capital with direct shareholdings like Meituan (03690), Xiaomi (01810), and Shoucheng Holdings (00697).
Data from Hong Kong Exchanges and Clearing Limited shows that the total open interest for Hang Seng Index futures (August) is 108,872 contracts, with net open interest at 31,354 contracts. The settlement date for Hang Seng Index futures is August 28, 2026. With the Hang Seng Index at 25,117 points, the area with a high concentration of bullish certificates is near the central axis, while bearish certificates are further away, indicating bearish sentiment in Hong Kong stocks. Wall Street traders have adjusted their expectations for Fed rate hikes. Hong Kong stocks are experiencing a rotation between sectors, with the Hang Seng Index expected to decline this week.
After a rapid rebound of approximately 12% from the end of June, Hong Kong stocks are likely to transition from a "fast phase of valuation recovery" to a "slow phase of earnings verification," with oscillating divergence expected to be the main theme. The recent rally was driven by a combination of low valuation recovery, short covering, and cross-market capital rebalancing. The Hang Seng Index's PE ratio has now returned to near its long-term average. The "easy stage" of broad-based gains is largely over. Further upside will require substantial improvement in corporate earnings. The current interim reporting season is a critical window to verify the rally's quality. Specifically, the progress of AI commercialization and the pace of margin recovery among Hang Seng Tech constituents will directly determine whether the growth sector can sustain the rally. Meanwhile, the Hang Seng Tech Index is about to undergo a review and expansion, broadening its tech theme coverage and increasing its constituents from 30 to 50 stocks. While beneficial for enhancing the index's representativeness and capital absorption capacity in the long run, this could cause short-term disruptions from index rebalancing and style rotation. On the capital flow front, the phase of joint boosting by domestic and foreign capital has passed. The pace of active foreign capital inflows has slowed, and southbound capital has also become more cautious. Market divergence will further intensify: core assets with strong earnings certainty will gradually realize their value, while a large number of small-cap stocks lacking fundamental support remain rife with "pump-and-dump" schemes involving share consolidation and rights issues, posing significant risks for ordinary investors. Overall, the bottom for Hong Kong stocks is clear, but a full reversal is still some way off. Rather than speculating on index movements, the next step is to position along the earnings improvement theme, focusing on areas like AI applications, healthcare, and high dividends, while resolutely avoiding small-cap stocks without earnings support, thereby securing certainty in a divergent market.
Comments